Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Merck and Moderna’s cancer vaccine deal; six pivotal trial readouts to look out for in Q4; Pfizer leads big pharma M&A so far this year; making the metaverse work in pharma; and a first approval for a Chinese mRNA vaccine.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 14 October 2022, including: Merck & Co., Inc. and Moderna, Inc.’s cancer vaccine deal; six pivotal trial readouts to look out for in Q4; Pfizer Inc. leads big pharma M&A so far this year; making the metaverse work in pharma; and a first approval for a Chinese mRNA vaccine.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option" - Scrip, 12 Oct, 2022.)
(Also see "Six Pivotal Trial Readouts To Look Out For In Q4" - Scrip, 11 Oct, 2022.)
(Also see "Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?" - Scrip, 12 Oct, 2022.)
(Also see "Doing It The Nike Way – Novartis, AstraZeneca On Making The Metaverse Work" - Scrip, 12 Oct, 2022.)
(Also see "Can First Approval Of China mRNA Vaccine Change 'COVID Zero' Approach?" - Scrip, 11 Oct, 2022.)